China Cell Therapy Market Opportunity & Clinical Trials Insight 2028
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
China Cell Therapy Market Opportunity & Clinical Trials Insight 2028 Report Highlights:
Immunotherapy has become one of the most sought after oncology treatments in recent years. China entered this industry slowly, but ever since it did, it has made enormous strides. CAR T Cell therapy is one of the most popular immunotherapies in China. Hundreds of CAR T Cell therapy candidates are currently undergoing clinical trials for the treatment of different diseases worldwide, around 20%-30% of which are being conducted in China, demonstrating the country's growing stature in the pharmaceutical industry. A large number of these clinical trials are being carried out against different forms of cancer, it being the leading cause of death in China and CAR-T cells have emerged as the front runner as the most used cells in the trials. Other immune cells like TIL and TCR have been tested in a fair share of clinical trials but their effectivity has been unsatisfactory which directed the attention of researchers in China towards the development CAR-T cells, which are genetically engineered human T lymphocytes.
The collection and incubation of CAR-T cells is a time taking process, wherein extra care has to be taken to prevent contamination. To help make this process simpler, many companies have developed proprietary technology platforms to encounter the various obstacles faced in the development process. For instance FasTCAR, developed by Gracell Bio, reduces the manufacturing time, improved the quality of the T-cells, among other additional benefits. There are many other platforms which have been constructed in recent times for the same purpose and have been the highlight of several partnerships in China’s cell therapy market.
FKC876 and Carteyva, the two CAR-T therapies that have been approved in China, are the products of two joint ventures that came into being, allowing the access of proprietary platforms of Kite Pharma and Juno Therapeutics to their Chinese partners, who then developed the drugs in mainland China. Neither of these two drugs is currently available in the market, nor have the companies revealed any plans of doing so, at least in the near future. Not only large pharma companies but even some CROs and CDMOs in China, like BioHeng, own innovative platforms that substantially reduce the manual effort and time which is invested in the maturation of these cells to be used in the treatment of severe diseases.
The major focus of researchers globally has been on the development autologous cell therapies; however they have now slowly directing their attention towards the development of allogeneic the cell therapies. These provide the same effects as autologous therapies but can be stored by hospitals, allowing a ready-for-use and quick treatment option. This trend has also seeped into the Chinese R&D sector, with clinical trials underway for different hematological malignancies.
The regulatory and policy framework has played the biggest role in this changing market dynamics in china. Historically being known for its slow integration towards western companies, its policies have since then evolved and have become more welcoming, urging the entry of more international companies in its pharma industry. This has not only given a boost to its pharma market but has also supported the growth of its domestic pharma companies by allowing the exchange of knowledge and proprietary technologies among companies in return for commercializing drugs developed by these western companies, in China and surrounding regions.
China’s pharma market has been growing rapidly over the last couple of years because of the interplay of several factors. As science and technology evolve and enter China, its cell therapy market, which is already constantly expanding to other indications, is expected to get a boost and will give the US strong competition in the future.
China Cell Therapy Market Opportunity & Clinical Trials Insight 2028 Report Highlights:
- More Than 400 Cell Therapies Are In Clinical Trials In China
- 2 Cell Therapies Are Commercially Approved
- Insight on More Than 25 Cell Therapies Proprietary Technologies Developed By Chines Companies
- China Cell Therapy Market Opportunity Assessment
- Insight On More Than 400 Cell Therapies In Clinical Trials By Phase, Indication, Company
- Analysis On Pricing & Reimbursement Framework
- Insight On Key Chinese Pharmaceutical Companies Involved In R&D OF Cell Therapies
Immunotherapy has become one of the most sought after oncology treatments in recent years. China entered this industry slowly, but ever since it did, it has made enormous strides. CAR T Cell therapy is one of the most popular immunotherapies in China. Hundreds of CAR T Cell therapy candidates are currently undergoing clinical trials for the treatment of different diseases worldwide, around 20%-30% of which are being conducted in China, demonstrating the country's growing stature in the pharmaceutical industry. A large number of these clinical trials are being carried out against different forms of cancer, it being the leading cause of death in China and CAR-T cells have emerged as the front runner as the most used cells in the trials. Other immune cells like TIL and TCR have been tested in a fair share of clinical trials but their effectivity has been unsatisfactory which directed the attention of researchers in China towards the development CAR-T cells, which are genetically engineered human T lymphocytes.
The collection and incubation of CAR-T cells is a time taking process, wherein extra care has to be taken to prevent contamination. To help make this process simpler, many companies have developed proprietary technology platforms to encounter the various obstacles faced in the development process. For instance FasTCAR, developed by Gracell Bio, reduces the manufacturing time, improved the quality of the T-cells, among other additional benefits. There are many other platforms which have been constructed in recent times for the same purpose and have been the highlight of several partnerships in China’s cell therapy market.
FKC876 and Carteyva, the two CAR-T therapies that have been approved in China, are the products of two joint ventures that came into being, allowing the access of proprietary platforms of Kite Pharma and Juno Therapeutics to their Chinese partners, who then developed the drugs in mainland China. Neither of these two drugs is currently available in the market, nor have the companies revealed any plans of doing so, at least in the near future. Not only large pharma companies but even some CROs and CDMOs in China, like BioHeng, own innovative platforms that substantially reduce the manual effort and time which is invested in the maturation of these cells to be used in the treatment of severe diseases.
The major focus of researchers globally has been on the development autologous cell therapies; however they have now slowly directing their attention towards the development of allogeneic the cell therapies. These provide the same effects as autologous therapies but can be stored by hospitals, allowing a ready-for-use and quick treatment option. This trend has also seeped into the Chinese R&D sector, with clinical trials underway for different hematological malignancies.
The regulatory and policy framework has played the biggest role in this changing market dynamics in china. Historically being known for its slow integration towards western companies, its policies have since then evolved and have become more welcoming, urging the entry of more international companies in its pharma industry. This has not only given a boost to its pharma market but has also supported the growth of its domestic pharma companies by allowing the exchange of knowledge and proprietary technologies among companies in return for commercializing drugs developed by these western companies, in China and surrounding regions.
China’s pharma market has been growing rapidly over the last couple of years because of the interplay of several factors. As science and technology evolve and enter China, its cell therapy market, which is already constantly expanding to other indications, is expected to get a boost and will give the US strong competition in the future.
1. CHINA CELL THERAPY MARKET INSIGHT
1.1 Current Market Trends
1.2 Approved Cell Therapies
2. CHINA CELL THERAPY MARKET COLLABORATIONS
3. CHINA CELL THERAPIES MARKET PROPRIETARY TECHNOLOGIES INNOVATION
3.1 Overview
3.2 Insight on Proprietary Technologies Developed By Chines Companies
4. DOMINANCE OF CAR-T THERAPY IN CHINA CELL THERAPY MARKET
5. CHINA CELL THERAPY PRICING & REIMBURSEMENT FRAMEWORK
5.1 Cell Therapy Pricing
5.2 Reimbursement Framework
6. CHINA CELL THERAPY PIPELINE OVERVIEW
6.1 By Company
6.2 By Indication
6.3 By Patient Segment
6.4 By Phase
7. CHINA CELL THERAPIES CLINICAL PIPELINE INSIGHT BY COMPANY, INDICATION & PHASE
7.1 Research
7.2 Preclinical
7.3 Clinical
7.4 Phase-0
7.5 Phase-I
7.6 Phase-I/II
7.7 Phase-II
7.8 Phase-II/III
7.9 Phase-III
7.10 Preregistration
7.11 Registered
8. MARKETED CELL THERAPIES CLINICAL INSIGHT
9. CHINA CELL THERAPY MARKET DYNAMICS
9.1 Market Drivers
9.2 Growth Restraints
10. CHINA CELL THERAPIES MARKET FUTURE OUTLOOK
10.1 Future Opportunity Insight
10.2 China Cell Therapy Contract Drug Manufacturing Opportunity
11. COMPETITIVE LANDSCAPE
11.1 Biocytogen
11.2 BRL Medicine
11.3 CARsgen Therapeutics
11.4 Cellular Biomedicine Group
11.5 Hebei Senlang Biotechnology
11.6 JW Therapeutics
11.7 Gracell Biotechnologies
11.8 Nanjing IASO Biotherapeutics
11.9 Nanjing KAEDI Biotech
11.10 PersonGen Biotherapeutics
11.11 TCRCure
11.12 Ubrigene
1.1 Current Market Trends
1.2 Approved Cell Therapies
2. CHINA CELL THERAPY MARKET COLLABORATIONS
3. CHINA CELL THERAPIES MARKET PROPRIETARY TECHNOLOGIES INNOVATION
3.1 Overview
3.2 Insight on Proprietary Technologies Developed By Chines Companies
4. DOMINANCE OF CAR-T THERAPY IN CHINA CELL THERAPY MARKET
5. CHINA CELL THERAPY PRICING & REIMBURSEMENT FRAMEWORK
5.1 Cell Therapy Pricing
5.2 Reimbursement Framework
6. CHINA CELL THERAPY PIPELINE OVERVIEW
6.1 By Company
6.2 By Indication
6.3 By Patient Segment
6.4 By Phase
7. CHINA CELL THERAPIES CLINICAL PIPELINE INSIGHT BY COMPANY, INDICATION & PHASE
7.1 Research
7.2 Preclinical
7.3 Clinical
7.4 Phase-0
7.5 Phase-I
7.6 Phase-I/II
7.7 Phase-II
7.8 Phase-II/III
7.9 Phase-III
7.10 Preregistration
7.11 Registered
8. MARKETED CELL THERAPIES CLINICAL INSIGHT
9. CHINA CELL THERAPY MARKET DYNAMICS
9.1 Market Drivers
9.2 Growth Restraints
10. CHINA CELL THERAPIES MARKET FUTURE OUTLOOK
10.1 Future Opportunity Insight
10.2 China Cell Therapy Contract Drug Manufacturing Opportunity
11. COMPETITIVE LANDSCAPE
11.1 Biocytogen
11.2 BRL Medicine
11.3 CARsgen Therapeutics
11.4 Cellular Biomedicine Group
11.5 Hebei Senlang Biotechnology
11.6 JW Therapeutics
11.7 Gracell Biotechnologies
11.8 Nanjing IASO Biotherapeutics
11.9 Nanjing KAEDI Biotech
11.10 PersonGen Biotherapeutics
11.11 TCRCure
11.12 Ubrigene
LIST OF FIGURES
Figure 1-1: China – Cell Therapy market Opportunity (US$ Million), 2022 - 2028
Figure 1-2: FKC876 –NMPA Approval Timeline
Figure 1-3: Carteyva – NMPA Approval Timeline
Figure 3-1: FasTCAR - Advantages
Figure 3-2: TruUCAR – Advantages
Figure 3-3: SMART CART – Advantages
Figure 3-4: CycloCAR – Mechanism Of Action
Figure 3-5: THANK-uCAR – Mechanism Of Action
Figure 3-6: - LADAR – Mechanism Of Action
Figure 3-7: IADDP - Advantages
Figure 3-8: SMART – Features
Figure 3-9: MADDS – Features
Figure 3-10: RenMice - Features
Figure 3-11: UCAR-T/NK – Advantages
Figure 3-12: UCAR-T/NK – Mechanism Of Action
Figure 3-13: PrecisionCAR – Advantages
Figure 3-14: PrecisionCAR – Mechanism Of Action
Figure 3-15: PRIMECAR® - Advantages
Figure 3-16: PRIMECAR® - Steps Of Preparation
Figure 3-17: RESCAR® - Mechanism Of Action
Figure 3-18: PhiCAR® - Mechanism Of Action
Figure 3-19: HyeCARTM - Advantages
Figure 3-20: HyeCARTM – Mechanism Of Action
Figure 3-21: TMR CAR-T – Working Condition
Figure 3-22: CCT3 CAR-T - Procedure
Figure 3-23: rPOC SC CAR-TaNKs - Structure
Figure 3-24: rPOC SC CAR-TaNKs - Procedure
Figure 3-25: G-CAR - Lymph Node Production
Figure 3-26: Ubrigene’s Cell Development Platform: Advantages
Figure 5-1: China – Yescarta Costs Comparison By Country (US$), September’2022
Figure 6-1: China – Cell Therapies Clinical Pipeline by Company, 2022 till 2028
Figure 6-2: China – Cell Therapies Clinical Pipeline by Indication, 2022 till 2028
Figure 6-3: China – Number of Cell Therapies In Clinical Pipeline by Patient Segment, 2022 till 2028
Figure 6-4: China – Number of Cell Therapies In Clinical Pipeline by Phase, 2022 till 2028
Figure 1-1: China – Cell Therapy market Opportunity (US$ Million), 2022 - 2028
Figure 1-2: FKC876 –NMPA Approval Timeline
Figure 1-3: Carteyva – NMPA Approval Timeline
Figure 3-1: FasTCAR - Advantages
Figure 3-2: TruUCAR – Advantages
Figure 3-3: SMART CART – Advantages
Figure 3-4: CycloCAR – Mechanism Of Action
Figure 3-5: THANK-uCAR – Mechanism Of Action
Figure 3-6: - LADAR – Mechanism Of Action
Figure 3-7: IADDP - Advantages
Figure 3-8: SMART – Features
Figure 3-9: MADDS – Features
Figure 3-10: RenMice - Features
Figure 3-11: UCAR-T/NK – Advantages
Figure 3-12: UCAR-T/NK – Mechanism Of Action
Figure 3-13: PrecisionCAR – Advantages
Figure 3-14: PrecisionCAR – Mechanism Of Action
Figure 3-15: PRIMECAR® - Advantages
Figure 3-16: PRIMECAR® - Steps Of Preparation
Figure 3-17: RESCAR® - Mechanism Of Action
Figure 3-18: PhiCAR® - Mechanism Of Action
Figure 3-19: HyeCARTM - Advantages
Figure 3-20: HyeCARTM – Mechanism Of Action
Figure 3-21: TMR CAR-T – Working Condition
Figure 3-22: CCT3 CAR-T - Procedure
Figure 3-23: rPOC SC CAR-TaNKs - Structure
Figure 3-24: rPOC SC CAR-TaNKs - Procedure
Figure 3-25: G-CAR - Lymph Node Production
Figure 3-26: Ubrigene’s Cell Development Platform: Advantages
Figure 5-1: China – Yescarta Costs Comparison By Country (US$), September’2022
Figure 6-1: China – Cell Therapies Clinical Pipeline by Company, 2022 till 2028
Figure 6-2: China – Cell Therapies Clinical Pipeline by Indication, 2022 till 2028
Figure 6-3: China – Number of Cell Therapies In Clinical Pipeline by Patient Segment, 2022 till 2028
Figure 6-4: China – Number of Cell Therapies In Clinical Pipeline by Phase, 2022 till 2028
